Financial Performance - The company's operating revenue for Q3 2022 reached RMB 2,770,325,079.67, representing a year-on-year increase of 138.25%[3] - Net profit attributable to shareholders for the same period was RMB 980,842,290.83, reflecting a significant increase of 269.40% compared to the previous year[3] - Basic earnings per share for Q3 2022 was RMB 2.58, up 134.55% year-on-year[3] - The company's operating revenue for the nine months ended September 30, 2022, was approximately $7.81 billion, representing a 167.25% increase compared to $2.92 billion for the same period in 2021[7] - The net profit for the nine months ended September 30, 2022, reached approximately $2.72 billion, a significant increase of 291.58% from $694.84 million in the previous year[8] - The company reported a net profit of RMB 994,018,270.14 for the current period, compared to a net loss of RMB 9,132,780.47 in the previous period[58] Assets and Liabilities - The total assets as of September 30, 2022, amounted to RMB 18,064,644,374.12, an increase of 19.19% from the end of the previous year[3] - The company's equity attributable to shareholders increased to RMB 15,062,075,186.72, a rise of 19.45% compared to the end of the previous year[3] - The total liabilities as of September 30, 2022, were RMB 2,589,270,696.37, up from RMB 2,204,806,672.76 at the start of the year, marking an increase of around 17.5%[18] - The company's total liabilities as of September 30, 2022, were RMB 3,002,569,187.40, compared to RMB 2,546,285,945.92 at the beginning of the year, representing an increase of approximately 17.9%[56] Cash Flow - Cash flow from operating activities for the year-to-date reached RMB 2,838,696,966.39, a substantial increase of 721.77%[3] - The net cash flow from operating activities for the year-to-date period was RMB 2,838,696,966.39, showing a remarkable growth of 721.77% compared to the previous year[40] - Cash inflow from operating activities generated ¥8,285,829,337.96, compared to ¥2,898,470,429.50 in the previous period, demonstrating improved cash generation[30] - Cash received from sales increased by 185.87% to approximately ¥8.29 billion compared to ¥2.90 billion in the same period last year, primarily due to increased operating income[46] Expenses - Research and development expenses increased by 71.93% to approximately $442.20 million, reflecting the company's commitment to technology-driven development[8] - The company reported a 403.49% increase in income tax expenses, amounting to approximately $400.74 million, driven by higher income and profit levels[8] - The company reported a substantial increase in financial expenses, with a change of 18,568.64%, primarily due to foreign exchange fluctuations affecting foreign currency assets[8] - Total operating costs amounted to ¥4,730,658,861.66, up from ¥2,257,068,855.39 in the previous period, reflecting a growth in expenses[21] Shareholder Returns - The company plans to distribute a cash dividend of RMB 8.00 per 10 shares, along with a capital reserve conversion of 4 additional shares for every 10 shares held[14] - The company repurchased a total of 3,425,263 shares, accounting for 1.0003% of the company's A shares, with a total repurchase fund of no less than RMB 400 million and not exceeding RMB 800 million[15] Market Expansion and Strategy - The company expanded its sales channels in domestic, Japan, and the U.S. markets, leading to a 50.17% increase in sales expenses to approximately $96.27 million[7] - The company plans to continue investing in R&D and expanding its market presence, focusing on emerging business areas and new product development[8]

Financial Performance - Revenue for the six months ended June 30, 2022, reached RMB 5,034,065 thousand, representing a 186.7% increase compared to RMB 1,755,569 thousand for the same period in 2021[14]. - Gross profit for the same period was RMB 2,363,225 thousand, up 200.9% from RMB 785,387 thousand year-over-year[14]. - Net profit attributable to shareholders for the six months ended June 30, 2022, was RMB 1,740,095 thousand, a significant increase of 305.3% from RMB 429,327 thousand in the prior year[14]. - The adjusted net profit attributable to shareholders, based on non-IFRS measures, was RMB 1,537,478 thousand, reflecting a 244.8% increase from RMB 445,943 thousand in the previous year[14]. - Basic earnings per share for the period was RMB 4.75, a 274.0% increase compared to RMB 1.27 for the same period in 2021[14]. - The gross margin improved to 46.9% from 44.7% year-over-year[14]. - The net profit margin attributable to shareholders increased to 34.6% from 24.5% in the prior year[14]. Market Position and Strategy - The company is the fifth largest innovative drug API CDMO globally and the largest commercial stage chemical drug CDMO in China, according to Frost & Sullivan's 2020 revenue statistics[21]. - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[13]. - Asymchem Laboratories continues to explore strategic partnerships and potential acquisitions to drive growth and innovation in the biopharmaceutical sector[13]. - Future outlook remains positive with expectations for continued revenue growth and improved profitability driven by increased demand for CDMO services[13]. - The company aims to expand its CDMO capabilities into new business areas, including large molecule CDMO, formulation, and clinical CRO services[24]. Operational Highlights - The company has established a research and production center for antibodies and ADC drugs in Shanghai, and a plasmid and mRNA business R&D base in Suzhou to meet the growing demand from domestic and international clients[25]. - The company has a production capacity of 10,000L/week for enzyme fermentation, with capabilities for high-quality production from milligram to ton scale[25]. - The company completed 34 commercial stage projects and 220 clinical stage projects during the reporting period, with 48 in clinical phase III[38]. - The company has developed over 2,400 enzymes, with 40% of them having proprietary IP, and has launched 15 enzyme reagent kits for rapid target enzyme screening[25]. - The company has established a synthetic biology technology R&D center since 2021, developing nearly 2,400 engineered enzymes and holding over 800 IPs across more than 20 categories[53]. Research and Development - R&D investment for the first half of 2022 reached RMB 263 million, a year-on-year increase of 60.67%, positioning the company among industry leaders[56]. - The newly created high-throughput screening and engineering modification technology platform aims to enhance the foundational capabilities in synthetic biology[59]. - The company is committed to continuous technological innovation and aims to develop internationally leading patented technologies for commercial production[126]. - The company is focusing on developing advanced drug delivery technologies to improve drug efficacy and reduce costs, addressing key industry challenges[59]. Financial Position and Cash Flow - The total equity attributable to shareholders was approximately RMB 14,586.17 million as of June 30, 2022, compared to RMB 6,287.10 million as of June 30, 2021[117]. - Cash and bank balances decreased by 7.5% from RMB 6,234.5 million as of December 31, 2021, to RMB 5,764.8 million as of June 30, 2022, primarily due to idle funds being used to purchase financial assets at fair value through profit or loss[106]. - Net cash flow from operating activities was RMB 631.78 million, an increase attributed to revenue growth, despite increased material ordering costs and timing differences in revenue recognition[116]. - Net cash flow used in investing activities was RMB 3,235.04 million, an increase of RMB 1,252.54 million, mainly due to capacity expansion, new technology investments, and the purchase of principal-protected short-term bank financial products[116]. Talent and Governance - The company has a workforce of 8,931 employees, with over 4,200 in R&D and analysis roles, and has recruited 110 senior talents in the first half of 2022[69]. - The management team has an average of 20 years of industry experience, emphasizing the company's strong leadership and commitment to talent development[78]. - The company is committed to enhancing its talent strategy and optimizing its organizational structure to improve operational efficiency and employee development[133]. - The company has adopted the corporate governance code and has complied with its principles throughout the reporting period, except for the separation of the roles of Chairman and CEO[177]. Risks and Challenges - The company has identified potential risks, including the risk of major innovative drugs being withdrawn from the market or recalled, and operational risks associated with clinical stage projects[134]. - The company has not recommended the payment of an interim dividend for the six months ended June 30, 2022[135].

Revenue and Profit Growth - Revenue for Q1 2022 reached ¥2,061,708,856.14, representing a 165.28% increase compared to ¥777,189,276.45 in the same period last year[3] - Net profit attributable to shareholders was ¥499,398,084.81, up 223.59% from ¥154,330,479.55 year-on-year[3] - Net profit excluding non-recurring gains and losses was ¥486,390,519.38, reflecting a 275.76% increase from ¥129,442,396.10 in the previous year[3] - Total revenue for Q1 2022 reached ¥2,061,708,856.14, a significant increase of 165.28% compared to ¥777,189,276.45 in Q1 2021, driven by strong growth in both small molecule and emerging businesses[7] - Net profit for Q1 2022 was ¥499,398,084.81, reflecting a 223.59% increase from ¥154,329,304.12 in Q1 2021, primarily due to increased operating income and controlled costs[7] - Total profit reached 567,088,566.35, compared to 165,290,678.28 in the prior period, indicating a growth of about 243%[21] Cash Flow and Liquidity - Operating cash flow net amount was ¥204,607,061.83, a 103.27% increase compared to ¥100,659,080.60 in the same period last year[3] - Cash flow from sales of goods and services was ¥1,855,113,552.16, a 102.89% increase from ¥914,340,633.86, attributed to higher sales revenue[8] - Cash and cash equivalents at the end of Q1 2022 totaled ¥5,642,739,406.29, representing an increase of 183.51% from ¥1,990,297,803.19 in Q1 2021[8] - The cash flow from operating activities amounted to 1,855,113,552.16, compared to 914,340,633.86 in the previous period, showing an increase of around 103%[24] - The cash flow from investing activities resulted in a net outflow of -1,131,790,662.67, compared to -239,398,407.60 in the prior period, indicating a larger investment outflow[27] - Cash flow from financing activities generated a net inflow of 383,841,586.32, compared to 10,625,287.78 in the previous period, marking a substantial increase[29] Assets and Liabilities - Total assets as of March 31, 2022, were ¥16,389,663,097.90, an 8.14% increase from ¥15,156,297,270.34 at the end of the previous year[3] - Total liabilities increased to CNY 2,875,485,236.77 from CNY 2,546,285,945.92, reflecting a rise of approximately 12.9%[16] - The company's total assets reached CNY 16,389,663,097.90, up from CNY 15,156,297,270.34, indicating a growth of about 8.1%[44] - Non-current liabilities totaled CNY 384,070,747.82, compared to CNY 341,479,273.16 at the beginning of the year, reflecting an increase of approximately 12.4%[46] Shareholder Equity and Earnings Per Share - Shareholders' equity attributable to the company was ¥13,514,177,861.13, a 7.17% increase from ¥12,610,011,324.42 at the end of the previous year[3] - Basic earnings per share increased to ¥1.91, up 198.44% from ¥0.64 year-on-year[3] - Basic earnings per share for the current period were 1.91, compared to 0.64 in the previous period, indicating a significant increase[22] Research and Development - R&D expenses increased by 56.86% to ¥130,883,695.56, up from ¥83,440,733.89, as the company continued to invest in technological innovation[7] - Research and development expenses increased to CNY 130,883,695.56 from CNY 83,440,733.89, indicating a growth of approximately 56.7%[18] Other Financial Metrics - The company reported government subsidies amounting to ¥13,007,565.43 during the period[3] - Investment income surged to ¥11,660,530.17, a dramatic increase of 13,369.67% from a loss of ¥87,873.58, due to profits from joint ventures[7] - The company made significant investments totaling ¥1,099,322,000.00 in financial products, a 7,228.81% increase from ¥15,000,000.00 in the previous year[8] - The company reported a decrease in other comprehensive income after tax of -6,310,310.96, compared to an increase of 2,378,209.88 in the previous period[21]

Financial Performance - Asymchem Laboratories reported a revenue of RMB 1.2 billion for the fiscal year 2021, representing a year-over-year growth of 25%[4] - The company's revenue for the reporting period was approximately RMB 4.63 billion, an increase of 47.7% compared to RMB 3.14 billion in the same period of 2020[18] - Gross profit for the reporting period was approximately RMB 2.05 billion, up 41.0% from RMB 1.45 billion in 2020[18] - Net profit attributable to shareholders was approximately RMB 1.07 billion, representing a 48.6% increase from RMB 719.74 million in 2020[18] - The company's total revenue for the reporting period reached RMB 4.632 billion, representing a year-on-year growth of 47.67%, and a growth of 56.38% when excluding exchange rate effects[35] - The net profit attributable to shareholders was RMB 1.069 billion, reflecting a year-on-year increase of 48.47%[39] - Revenue increased by 47.7% from RMB 3,136.7 million in 2020 to RMB 4,632.1 million in 2021, driven by a 46.02% growth in small molecule CDMO business[70] - Commercialization revenue grew by 52.11% to RMB 2,511.3 million, accounting for 54.22% of total revenue[71] - Revenue from emerging services increased by 67.88% to RMB 397.0 million, representing 8.57% of total revenue[71] Market Expansion and Strategy - Asymchem is expanding its market presence in Europe and North America, with plans to establish new partnerships and collaborations[4] - The company plans to actively expand into new markets, particularly the US biotech market, to support future growth[17] - The company aims to enhance its comprehensive competitiveness by ensuring high-quality delivery of large orders and expanding its global market share, particularly in the small molecule CDMO business[112] - In 2022, the company plans to increase its small molecule production capacity by over 2,000m³, with new facilities in Dunhua, Tianjin, and the Yangtze River Delta region[118] - The company is focusing on accelerating the development of new drug categories and service types, including advancing small nucleic acid CDMO services and establishing a strong presence in clinical research services[114] Research and Development - The company is investing RMB 200 million in R&D for new product development, focusing on biologics and advanced drug delivery systems[4] - R&D investment reached 387 million RMB, a year-on-year increase of 49.64%, accounting for 8.37% of total revenue, positioning the company among the global industry leaders[57] - The company established four R&D technology platforms to address project development challenges and enhance innovation capabilities[57] - The company is increasing its investment in R&D to ensure a higher application ratio of new technologies, maintaining its technological edge in the industry[119] Operational Efficiency and Capacity - The company reported a significant increase in production capacity, with a 40% rise in output from its Tianjin facility[4] - The company has successfully expanded its CDMO capabilities to include new drug categories such as peptides, oligonucleotides, and mRNA[32] - The company optimized the synthesis process for an innovative anti-tumor drug, reducing the production cycle from 130 days to under 60 days, increasing yield by nearly 300%[46] - The company has implemented continuous reaction technology, achieving a production capacity of 1.3 tons per day for key raw materials, which would require 180m³ of batch capacity to produce the same scale[65] Sustainability and Corporate Responsibility - The company emphasized its commitment to sustainability, with plans to reduce carbon emissions by 30% by 2025[4] - The company has implemented environmental policies and measures to reduce energy consumption and waste, demonstrating its commitment to sustainability[157] Corporate Governance and Management - The board consists of nine members, including four executive directors, two non-executive directors, and three independent non-executive directors[126] - The company has a strong focus on operational and financial supervision, with key personnel responsible for these areas having extensive backgrounds in management and finance[135] - The management structure includes a mix of long-serving members and new appointees, fostering continuity and fresh perspectives[137] - The company emphasizes corporate governance and daily operations management, led by Xu Xiangke, who has extensive experience in corporate affairs[142] Financial Position and Investments - Total assets increased to approximately RMB 15.16 billion, while total liabilities rose to RMB 2.55 billion, resulting in a debt-to-asset ratio of 16.8%[22] - Cash and cash equivalents increased by 193.4% from RMB 2,124.6 million in 2020 to RMB 6,234.5 million in 2021, mainly due to funds raised from a global offering[93] - The company completed the issuance of H-shares, raising approximately HKD 6.85 billion, which will be used to strengthen global operations and enhance CDMO capabilities[68] Talent Management and Human Resources - The company has a workforce of 7,126 employees, with 3,381 in R&D and analysis roles, accounting for 47.45% of the total[66] - The company focuses on talent management and has established mechanisms for talent selection, evaluation, and incentives to enhance its human resources strategy[123] - The company introduced 49 senior talents during the reporting period, including 18 PhDs and 16 senior executives, to enhance its drug development ecosystem[66] Risks and Challenges - Potential risks include the risk of major innovative drugs being withdrawn from the market, operational risks in clinical projects, and lifecycle replacement risks of key innovative drugs[124] - The company has faced challenges such as regulatory scrutiny from international drug authorities and the potential loss of core technical personnel[124]